Gracell Biotechnologies Inc.

About Gracell Biotechnologies Inc.

Gracell is a global clinical-stage biopharmaceutical company focused on discovering and developing innovative cell therapies to address major industry challenges and unmet medical needs in the treatment of cancer and autoimmune diseases. Their mission is to deliver fast, deep, and durable responses through pioneering technologies.

Products & Services

FasTCAR™:A platform utilizing next-day manufacturing to generate younger, less exhausted CAR-T cells with potentially enhanced activities.

TruUCAR™:An allogeneic platform to develop off-the-shelf CAR-T cell therapies, aiming to make cell therapy accessible to more patients.

SMART CART™:A 2nd generation enhanced CAR-T molecule designed to tackle challenges in treating solid tumors.

Specialties

CAR-T Cell Therapies Cancer Treatment Autoimmune Disease Treatment Cell Therapy Innovation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Private Placement T: - FT: Private Placement	A: 150000000 MR: - FA: up to $150 million FAN: 150000000	D: 2023-08-07 FD: 2023-08-07	9 investors

Private Placement Latest

2023-08-07

$150.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

W

William Wei Cao

Founder

Recent News